Physician

Sandy Diana Kotiah, M.D.

According to 2025 Medicare claims, Sandy Kotiah, M.D. (NPI: 1104035971) practices hematology/oncology in the Baltimore-Columbia-Towson, MD market, with the plurality of this provider's patient population coming from Baltimore, MD. This provider's primary affiliated billing organization is LUTHERVILLE HEMATOLOGY AND ONCOLOGY SERVICES (NPI: 1538454228; TIN: 27-4697590) and primary practice location at 21093-5606. Kotiah is affiliated with the ACO West Virginia (ACO ID: A3563) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Kotiah's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,169 traditional Medicare patients, billed 210,657 HCPCS/CPT codes, and received $4,406,543 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 837 prescription claims across 313 beneficiaries totaling $377,089 in drug costs, led by Abiraterone Acetate (Abiraterone Acetate). 2022 DME data shows 22 claims. Open Payments data shows 133 records totaling $20,494. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $124,518 to $4,406,543. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $376,362 and ending at $377,089. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $12,992 to $3,207.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	493	1,558	$124,518
2016	598	5,074	$172,497
2017	660	15,554	$338,550
2018	803	54,341	$914,566
2019	807	27,569	$461,361
2020	860	43,280	$1,006,210
2021	812	56,715	$1,213,598
2022	931	80,620	$1,677,988
2023	1,004	83,074	$1,350,178
2024	1,169	210,657	$4,406,543

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	204	888	$376,362
2016	248	1,211	$423,113
2017	255	1,306	$910,912
2018	274	958	$670,833
2019	323	1,235	$930,475
2020	288	1,121	$739,801
2021	251	779	$537,751
2022	246	683	$475,078
2023	253	648	$279,756
2024	313	837	$377,089

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	168	$13,056
2016	N/R	137	$22,229
2017	N/R	63	$13,581
2018	N/R	44	$13,147
2019	N/R	55	$34,056
2020	N/R	46	$1,015
2021	N/R	61	$1,265
2022	N/R	22	$557
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	536	834	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	276	315	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	576	833	$13
96372	Injection of drug or substance under skin or into muscle	177	428	$12
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	190	615	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Abiraterone Acetate	Abiraterone Acetate	12	465	$82,277
Eliquis	Apixaban	60	3,960	$74,930
Xarelto	Rivaroxaban	41	2,430	$43,406
Anastrozole	Anastrozole	84	7,440	$3,289
Letrozole	Letrozole	58	5,150	$1,847

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	133	$20,494	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sandy Diana Kotiah, M.D.?

Tedicare shows public-source Medicare data for Sandy Diana Kotiah, M.D. (NPI 1104035971), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sandy Diana Kotiah, M.D. have ACO affiliation data?

Sandy Diana Kotiah, M.D. is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Sandy Diana Kotiah, M.D.?

Sandy Diana Kotiah, M.D. is linked to LUTHERVILLE HEMATOLOGY AND ONCOLOGY SERVICES (billing NPI 1538454228) in the available physician profile data.

Does Sandy Diana Kotiah, M.D. have Open Payments data?

Sandy Diana Kotiah, M.D. has 133 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.